Sells clonoSEQ tests and research services that measure residual cancer and map immune receptors for clinicians, biopharmaceutical companies, researchers and academic institutions.
10-K for FY2025, filed Feb 26, 2026The MRD business focuses on the use of our highly sensitive, next-generation sequencing (“NGS”) assay to measure MRD in patients with…View ↗
The IM business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors (“BCRs”) at scale. We…View ↗
The MRD business focuses on the use of our highly sensitive, FDA-authorized NGS assay to measure MRD in patients with hematologic…View ↗
We offer our core clonoSEQ technology to two primary customer segments: we work with clinicians to provide clonoSEQ clinical diagnostic…View ↗
Clinicians order clonoSEQ reports for patients, with commercial, government and medical institution payors paying for them. Biopharmaceutical companies and some academic institutions use MRD sample testing in drug development; international laboratory sites receive clonoSEQ results through technology transfers.
10-K for FY2025, filed Feb 26, 2026
No. It lost $59.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $268 million and $278 million, updated from the…View ↗
8-K, filed Jun 15, 2026
Also on June 15, 2026, the Company issued a second press release announcing its intention to pursue a separation of its Minimal Residual…View ↗
Loading...